Summit’s biomarker data has the potential to monitor utrophin modulation activity and distinguish between repairing and mature muscle fibres in DMD muscle biopsies at the single fibre level. This promising biomarker programme will support and help inform the development of SMT C1100, Summit’s lead utrophin modulator, and its second and future utrophin modulators. SMT C1100 met its primary objective in its Phase Ib modified diet clinical trial in August and received approval to initiate a Phase I ....
